Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis

Kazuki Sakai, Eri Kawata, Eishi Ashihara, Yoko Nakagawa, Akira Yamauchi, Hisayuki Yao, Rina Nagao, Ruriko Tanaka, Asumi Yokota, Miki Takeuchi, Hideyo Hirai, Shinya Kimura, Mitsuomi Hirashima, Norio Yoshimura, Taira Maekawa

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Galectins comprise a family of animal lectins that differ in their affinity for β-galactosides. Galectin-9 (Gal-9) is a tandem-repeat-type galectin that was recently shown to function as a ligand for T-cell immunoglobin domain and mucin domain-3 (Tim-3) expressed on terminally differentiated CD4+ Th1 cells. Gal-9 modulates immune reactions, including the induction of apoptosis in Th1 cells. In this study, we investigated the effects of Gal-9 in murine models of acute GVH disease (aGVHD). First, we demonstrated that recombinant human Gal-9 inhibit MLR in a dose-dependent manner, involving both Ca2+ influx and apoptosis in T cells. Next, we revealed that recombinant human Gal-9 significantly inhibit the progression of aGVHD in murine BM transplantation models. In conclusion, Gal-9 ameliorates aGVHD, possibly by inducing T-cell apoptosis, suggesting that gal-9 may be an attractive candidate for the treatment of aGVHD.

Original languageEnglish
Pages (from-to)67-75
Number of pages9
JournalEuropean Journal of Immunology
Volume41
Issue number1
DOIs
Publication statusPublished - Jan 1 2011
Externally publishedYes

Fingerprint

Galectins
Acute Disease
Apoptosis
T-Lymphocytes
Th1 Cells
Mucin-3
Galactosides
Tandem Repeat Sequences
Lectins
Transplantation
Ligands

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Sakai, K., Kawata, E., Ashihara, E., Nakagawa, Y., Yamauchi, A., Yao, H., ... Maekawa, T. (2011). Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. European Journal of Immunology, 41(1), 67-75. https://doi.org/10.1002/eji.200939931

Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. / Sakai, Kazuki; Kawata, Eri; Ashihara, Eishi; Nakagawa, Yoko; Yamauchi, Akira; Yao, Hisayuki; Nagao, Rina; Tanaka, Ruriko; Yokota, Asumi; Takeuchi, Miki; Hirai, Hideyo; Kimura, Shinya; Hirashima, Mitsuomi; Yoshimura, Norio; Maekawa, Taira.

In: European Journal of Immunology, Vol. 41, No. 1, 01.01.2011, p. 67-75.

Research output: Contribution to journalArticle

Sakai, K, Kawata, E, Ashihara, E, Nakagawa, Y, Yamauchi, A, Yao, H, Nagao, R, Tanaka, R, Yokota, A, Takeuchi, M, Hirai, H, Kimura, S, Hirashima, M, Yoshimura, N & Maekawa, T 2011, 'Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis', European Journal of Immunology, vol. 41, no. 1, pp. 67-75. https://doi.org/10.1002/eji.200939931
Sakai, Kazuki ; Kawata, Eri ; Ashihara, Eishi ; Nakagawa, Yoko ; Yamauchi, Akira ; Yao, Hisayuki ; Nagao, Rina ; Tanaka, Ruriko ; Yokota, Asumi ; Takeuchi, Miki ; Hirai, Hideyo ; Kimura, Shinya ; Hirashima, Mitsuomi ; Yoshimura, Norio ; Maekawa, Taira. / Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. In: European Journal of Immunology. 2011 ; Vol. 41, No. 1. pp. 67-75.
@article{a5941d408b93487ba6cf5fff48cc32b7,
title = "Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis",
abstract = "Galectins comprise a family of animal lectins that differ in their affinity for β-galactosides. Galectin-9 (Gal-9) is a tandem-repeat-type galectin that was recently shown to function as a ligand for T-cell immunoglobin domain and mucin domain-3 (Tim-3) expressed on terminally differentiated CD4+ Th1 cells. Gal-9 modulates immune reactions, including the induction of apoptosis in Th1 cells. In this study, we investigated the effects of Gal-9 in murine models of acute GVH disease (aGVHD). First, we demonstrated that recombinant human Gal-9 inhibit MLR in a dose-dependent manner, involving both Ca2+ influx and apoptosis in T cells. Next, we revealed that recombinant human Gal-9 significantly inhibit the progression of aGVHD in murine BM transplantation models. In conclusion, Gal-9 ameliorates aGVHD, possibly by inducing T-cell apoptosis, suggesting that gal-9 may be an attractive candidate for the treatment of aGVHD.",
author = "Kazuki Sakai and Eri Kawata and Eishi Ashihara and Yoko Nakagawa and Akira Yamauchi and Hisayuki Yao and Rina Nagao and Ruriko Tanaka and Asumi Yokota and Miki Takeuchi and Hideyo Hirai and Shinya Kimura and Mitsuomi Hirashima and Norio Yoshimura and Taira Maekawa",
year = "2011",
month = "1",
day = "1",
doi = "10.1002/eji.200939931",
language = "English",
volume = "41",
pages = "67--75",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "1",

}

TY - JOUR

T1 - Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis

AU - Sakai, Kazuki

AU - Kawata, Eri

AU - Ashihara, Eishi

AU - Nakagawa, Yoko

AU - Yamauchi, Akira

AU - Yao, Hisayuki

AU - Nagao, Rina

AU - Tanaka, Ruriko

AU - Yokota, Asumi

AU - Takeuchi, Miki

AU - Hirai, Hideyo

AU - Kimura, Shinya

AU - Hirashima, Mitsuomi

AU - Yoshimura, Norio

AU - Maekawa, Taira

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Galectins comprise a family of animal lectins that differ in their affinity for β-galactosides. Galectin-9 (Gal-9) is a tandem-repeat-type galectin that was recently shown to function as a ligand for T-cell immunoglobin domain and mucin domain-3 (Tim-3) expressed on terminally differentiated CD4+ Th1 cells. Gal-9 modulates immune reactions, including the induction of apoptosis in Th1 cells. In this study, we investigated the effects of Gal-9 in murine models of acute GVH disease (aGVHD). First, we demonstrated that recombinant human Gal-9 inhibit MLR in a dose-dependent manner, involving both Ca2+ influx and apoptosis in T cells. Next, we revealed that recombinant human Gal-9 significantly inhibit the progression of aGVHD in murine BM transplantation models. In conclusion, Gal-9 ameliorates aGVHD, possibly by inducing T-cell apoptosis, suggesting that gal-9 may be an attractive candidate for the treatment of aGVHD.

AB - Galectins comprise a family of animal lectins that differ in their affinity for β-galactosides. Galectin-9 (Gal-9) is a tandem-repeat-type galectin that was recently shown to function as a ligand for T-cell immunoglobin domain and mucin domain-3 (Tim-3) expressed on terminally differentiated CD4+ Th1 cells. Gal-9 modulates immune reactions, including the induction of apoptosis in Th1 cells. In this study, we investigated the effects of Gal-9 in murine models of acute GVH disease (aGVHD). First, we demonstrated that recombinant human Gal-9 inhibit MLR in a dose-dependent manner, involving both Ca2+ influx and apoptosis in T cells. Next, we revealed that recombinant human Gal-9 significantly inhibit the progression of aGVHD in murine BM transplantation models. In conclusion, Gal-9 ameliorates aGVHD, possibly by inducing T-cell apoptosis, suggesting that gal-9 may be an attractive candidate for the treatment of aGVHD.

UR - http://www.scopus.com/inward/record.url?scp=78650349323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650349323&partnerID=8YFLogxK

U2 - 10.1002/eji.200939931

DO - 10.1002/eji.200939931

M3 - Article

C2 - 21182078

AN - SCOPUS:78650349323

VL - 41

SP - 67

EP - 75

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 1

ER -